Sangeeta Goswami, M.D., Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor / Joint Appointment (Tenured), Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor (Tenured), Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Member, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor (Tenured), Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor (Tenured), Immunology (Joint Appointment), The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2009 | Baylor College of Medicine, Houston, Texas, US, Immunology, Ph.D |
| 2001 | Gauhati Medical College, Assam, IN, M.D |
Postgraduate Training
| 2013-2016 | Clinical Fellowship, Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2013 | Clinical Residency, Internal Medicine, The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania |
Licenses & Certifications
| 2016 | American Board of Internal Medicine-Medical Oncology |
| 2016 | Texas Medical Board |
| 2015 | American Board of Internal Medicine-Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor (Tenured Track), Immunology (Joint Appointment), The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2024
Assistant Professor (Tenured Track), Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Advanced Scholar, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2018
Administrative Appointments/Responsibilities
MD Anderson Cancer Center Scientific Research Committee (SRC), The University of Texas MD Anderson Cancer Center, Houston, Texas
Member, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas
Epigenomics Profiling Core Advisory Board, The University of Texas MD Anderson Cancer Center, Houston, Texas
Steering Committee Member, Cancer Neuroscience Working Groups, The University of Texas MD Anderson Cancer Center, Houston, Texas
Steering Committee Member, Myeloid Working Group, The University of Texas MD Anderson Cancer Center, Houston, Texas
Member, MD Anderson Cancer Center Immunotherapy Platform Working Group, The University of Texas MD Anderson Cancer Center, Houston, Texas
Extended Leadership Committee Member of Glioblastoma (GBM) Team, BreakThrough Cancer Initiative, Houston, Texas
Other Professional Positions
Scientific Advisory Board, Daiichi Sankyo, Basking Ridge, New Jersey, 2023 - Present
Advisory Board, Astellas/SeaGen, Houston, Texas, 2022 - Present
Consulting, Inzen Therapeutics, Watertown, Massachusetts, 2022 - Present
Postdoctoral Research Fellow, The University of Texas MD Anderson Cancer Center - Thoracic/Head and Neck Medical Oncology, Houston, TX, 2009 - 2011
Research Associate, Institute of Genomics and Integrative Biology - Immunogenetics Laboratory, New Delhi, 2002 - 2003
Junior Resident Doctor, Sacred Home Hospital and Research Center, Ulibarri, 2001 - 2002
Extramural Institutional Committee Activities
Faculty, T32 Grant, Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2024 - Present
Organizing Committee, Society for Immunotherapy of Cancer (SITC) Women in Cancer Immunotherapy Network (WIN) Institute Organizers, NIH/SITC, 2024 - Present
Co-Mentor, Brain Tumor Center (BTC) T32 Grant, BTC, 2024 - Present
Search Committee, Genitourinary Medical Oncology/Radiation Oncology Chair Candidate Search Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, CPRIT Translational Research Multi-Disciplinary Program (TRIUMPH) Fellowship Program, The University of Texas MD Anderson Cancer Center, 2023 - Present
Advisory Board Member, The University of Texas MD Anderson Cancer Center Epigenomics Profiling Core, The University of Texas MD Anderson Cancer Center, 2023 - Present
Mentor, Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) Program, The University of Texas MD Anderson Cancer Center, 2023 - Present
Organizing Committee Member, The University of Texas MD Anderson Cancer Center Organizing Committee, 2022 Symposia on Cancer Research, The University of Texas MD Anderson Cancer Center, 2022 - Present
Steering Committee Member, The University of Texas MD Anderson Cancer Center Cancer Neuroscience Working Groups, The University of Texas MD Anderson Cancer Center, 2022 - Present
Co-Chair, MD Anderson Cancer Research Symposium, The University of Texas MD Anderson Cancer Center, 2022 - Present
Steering Committee Member, The University of Texas MD Anderson Cancer Center Myeloid Diversity Interest Group, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, The University of Texas MD Anderson Cancer Center Scientific Research Committee (SRC), The University of Texas MD Anderson Cancer Center, 2019 - Present
Committee Member, Odyssey Fellowship Review Committee, Member, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, The University of Texas MD Anderson Cancer Center Organizing Committee, 2019 Symposia on Cancer Research, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, The University of Texas MD Anderson Cancer Center Odyssey High Impact Research Publication Award Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, The University of Texas MD Anderson Cancer Center Odyssey Fellowship Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Committee Member, Odyssey High Impact Research Publication Award Review Committee, Member, The University of Texas MD Anderson Cancer Center, 2019 - Present
Editorial Activities
Associate Editor, Science Advances, 2026 - Present
Guest Editor, Frontiers in Immunology, 2021
Member of Editorial Review Board, Frontiers in Immunology, 2016
Honors & Awards
| 2025 - Present | Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2025 - Present | Research Excellence, The University of Texas MD Anderson Cancer Center |
| 2025 - Present | Top 1% Provider in the Nation, Press Ganey's Database |
| 2024 - Present | Emil Frei, III Award for Excellence in Translational Research - Nominated, The University of Texas MD Anderson Cancer Center |
| 2024 - Present | Invited by the White House to be a Panelist for the Inaugural US-India Cancer Dialogue, White House, USA |
| 2024 - Present | Medical Spotlight Featuring Dr. Sangeeta Goswami, MedNews Week |
| 2024 - Present | Invited to the National Cancer Institute (NCI) Division of Cancer Biology (DCB) Workshop, National Cancer Institute |
| 2023 - Present | Inaugural Member, James P. Allison Institute |
| 2021 - Present | Andrew Sabin Fellowship, The University of Texas MD Anderson Cancer Center |
| 2019 - Present | Tang Fellowship in Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center |
| 2018 - Present | The Parker Institute of Cancer Immunotherapy (PICI) Physician-Scientist Award, PICI |
| 2016 - Present | Waun Ki Hong Award for Achievement in Basic Science Research, The University of Texas MD Anderson Cancer Center |
| 2016 - Present | American Society of Clinical Oncology (ASCO) Merit Award, ASCO |
| 2007 - Present | Outstanding Presentation-Basic Research, Department of Medicine Research Symposium, Baylor College of Medicine |
| 2006 - Present | Best Poster Presentation, Department of Immunology, Baylor College of Medicine |
| 2005 - Present | Best Research Proposal in Clinical Immunology, Baylor College Medicine |
| 2001 - Present | Certification of Honor, Gauhati Medical College, India |
| 1996 - Present | National Technical Scholarship, India, National Technical Education |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Leveraging epigenetic regulation to improve response to cancer immunotherapy. Invited. Center for Cancer Epigenetics 2026 Annual Retreat. Houston, Texas, US.
- 2026. Curative Intent MIBC. Panelist. HOLI: Clinical Immersion in Bladder Cancer. Houston, Texas, US.
- 2026. Multi-Omics Bridging the Gap between Basic Science and Clinical Care. Panelist. 2026 IOTOX Symposium. Houston, Texas, US.
- 2026. Mechanism-Guided Design of Next-Generation Immunotherapy Combinations Across Tumor Types. Invited. Molecular Oncology Distinguished Scientist Seminar Series. Houston, Texas, US.
- 2026. Targeting Epigenetic Machinery to Overcome Therapeutic Resistance. Invited. 2026 International Cancer Neuroscience Symposium. Houston, Texas, US.
- 2025. Epigenetic Modulators of Immunotherapy Response and Resistance in Bladder Cancer. Invited. 3rd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2024. Targeting the Eipgenetic Machinery to improve response to Immune Checkpoint Therapy. Invited. Brain Tumor Program Seminar series. Houston, Texas, US.
- 2024. The Epigenetic Regulation of T Cell Function. Invited. The Annual Center for Cancer Epigenetics Retreat (CCE’24). Houston, Texas, US.
- 2024. The Topic of Bladder Cancer. GU Lecture Series. Houston, Texas, US.
- 2024. KDM6B Improves Efficacy of PDL1 Inhibitors to Glioblastoma. Invited. MedNews Week. Virtual, Texas, US.
- 2023. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Invited. James P. Allison Institute Sympsium. Houston, Texas, US.
- 2023. Targeting Epigenetic Pathways to Improve Response to Immune Checkpoint Therapy in Genitourinary Malignancies. Invited. 2023 UT Christopher G. Wood Advances in Urologic Oncology Meeting. Houston, Texas, US.
- 2023. Elucidating the therapeutic vulnerabilities of the epigenetic machinery to imptove responses to immune checkpoint therapy. Invited. Department of Cancer Biology Wednesday Seminar Series. Houston, Texas, US.
- 2022. Updates on Bladder Cancer Treatment and Management. Invited. Baylor College of Medicine. Houston, Texas, US.
- 2022. Targeting immunosuppressive myeloid cells within the TME. Invited. The University of Texas MD Anderson Cancer Center Department of Genitourinary Medical Oncology. Houston, Texas, US.
- 2022. Pathway to Becoming a Physician Scientist. Invited. Department of Interventional Radiology- Summer Experience & Odyssey Programs in Education & Training. Houston, Texas, US.
- 2021. Pathway of Response and Resistance to Immune Checkpoint Therapy. Invited. General Internal Medicine group at their Clinical and Research Conference, US.
- 2021. Bladder Cancer Updates and Management. Invited. Grand Rounds Presentation. Houston, Texas, US.
- 2020. Epigenetic Regulation of Immune Microenvironment. Invited. CCGS Immunology and Cancer Genetics & Epigenetics Retreat. Houston, Texas, US.
- 2019. Arid1a Mutation Plus Cxcl13 Expression Act as Combinatorial Biomarkers to Predict Responses to Immune Checkpoint Therapy in Urothelial Carcinoma. Invited. Leading Edge in Cancer Research. Houston, Texas, US.
- 2019. Symposium on Cancer Research. Invited. Houston, Texas, US.
- 2018. Immunotherapy for Bladder Cancer. Invited. MD Anderson and OncInfo Roche Preceptorship. Houston, Texas, US.
- 2018. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. Invited. Melvin Samuels Lectureship. Houston, Texas, US.
Regional Presentations
- 2026. Leveraging epigenetic regulation to improve response to cancer immunotherapy. Invited. Center for Cancer Epigenetics Annual Retreat 2026. Round Rock, Texas, US.
National Presentations
- 2025. Immune Checkpoint Inhibitors in Metastatic RCC: Lesson Learned from Clinics. Invited. International Kidney Cancer Symposium: North America (IKCSNA25). Denver, Colorado, US.
- 2025. Deciphering the Pathways of Response and Resistance to Immune Checkpoint Therapy. Invited. 7th Annual Cholangiocarcinoma Summit. Scottsdale, Arizona, US.
- 2025. Women and Work: Alternate Career Path. Panelist. The 7th Annual Women in Cancer Immunotherapy Network (WIN) Leadership Institute. Chicago, Illinois, US.
- 2025. Improving Immune Checkpoint Therapy Responses by Leveraging Fundamental Science and Clinical Data. Invited. The Landscapte of Cancer Research, US.
- 2025. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Blockade. Invited. Coffey-Holden Prostate Cancer Academy. Los Angeles, California, US.
- 2025. Clinical Trials Plenary entitled, Biologics and T-cell Engagers. Panelist. AACR Annual Meeting 2025. Chicago, IL, US.
- 2025. Physician Scientist Career Development Panel. Panelist. 5th Annual Sylvester K12 Calabresi Symposium, US.
- 2024. The Epigenetic Regulation of T Cell-Mediated Anti-Tumor Immunity. Conference. The Epigenetic Regulation of T Cell-Mediated Anti-Tumor Immunity. Houston, TX, US.
- 2024. Intersection of Immunology and the Epigenome in Cancer Therapeutics. Conference. Visiting Professor Series. Virtual, US.
- 2024. Integrating Biomarkers Into Bladder Cancer Clinical Trials. Conference. Integrating Biomarkers Into Bladder Cancer Clinical Trials. Baltimore, MD, US.
- 2024. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. American Urological Association (AUA)-Johns Hopkins University (JHU) Greenberg Bladder Cancer Institute (GBCI) Bladder Cancer Research Symposium, "Integrating Biomarkers Into Bladder Cancer Clinical Trials". Baltimore, MD, US.
- 2024. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. Elkin Lecture. Atlanta, GA, US.
- 2024. Medical Spotlight Featuring Dr. Sangeeta Goswami. Conference. Medical Spotlight Featuring Dr. Sangeeta Goswami. Virtual (www.mednewsweek.com), US.
- 2023. Targeting Epigenetic Pathways to Improve Response to Immune Checkpoint Therapy. Conference. European Association of Cancer Research.
- 2023. Global Summit on Genitourinary Malignancies. Conference. 2023 Colorado Spring GU Summit. Colorado Springs, CO, US.
- 2023. Immune Checkpoint Blockade. Conference. Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting & Pre-Conference Programs. San Diego, CA, US.
- 2023. Opinions in Genitourinary Cancers: An Interactive Regional Forum. Opinions in Genitourinary Cancers: An Interactive Regional Forum. Salt Lake City, UT, US.
- 2023. Women in Cancer Immunotherapy Network (WIN) Session 2: How to Develop Your Team. Conference. WIN Leadership Institute 2023. Chicago, IL, US.
- 2023. Women in Cancer Immunotherapy Network (WIN) Session 1: The Art of Saying No. Conference. WIN Leadership Institute 2023. Chicago, IL, US.
- 2023. Targeting Epigenetic Machinery to Improve Response to Immune Checkpoint Therapy. Conference. New York Academy of Sciences (NYAS). New York, NY, US.
- 2023. Targeting Epigenetic Pathways to Improve Response to Immune Checkpoint Therapy in Genitourinary Malignancies. Conference. 2023 UT Christopher G. Wood Advances in Urologic Oncology Meeting. Austin, TX, US.
- 2023. Elucidating the Therapeutic Vulnerabilities of the Epigenetic Machinery to Improve Responses to Immune Checkpoint Therapy. Conference. Department of Cancer Biology. Houston, US.
- 2023. Updates on Bladder Cancer Treatment and Management. Conference. Faculty Speakers Bureau. Houston, TX, US.
- 2022. Immune Checkpoint Blockade. Conference. SITC’s Primer on Tumor Immunology and Cancer Immunotherapy and Session Co-Chair to the SITC 37th Annual Meeting. Boston, MA, US.
- 2022. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. The Allison Institute Seminar Series. Houston, TX, US.
- 2022. Updates on Bladder Cancer Treatment and Management. Conference. Baylor College of Medicine. Houston, TX, US.
- 2022. Breakthrough Cancer: Translating Findings from Genitourinary Cancer. Conference. Board of Visitors. Houston, TX, US.
- 2022. Targeting Immunosuppressive Myeloid Cells within the TME. Conference. Prostate Moon Shot. Virtual Meeting, TX, US.
- 2022. Immunotherapy for Kidney Cancer. Conference. 2022 Cancer Research Institute (CRI) Immunotherapy Patient Summit. Virtual Meeting, TX, US.
- 2022. Immune Checkpoint Therapy in Cancer: Current Challenges and Future Directions. Conference. Guest Lecture in Beyond the Horizon: Guest Lecture Series in Oncology, Dr. Bhubaneswar Borooah Cancer Institute (BBCI). Virtual Meeting, US.
- 2022. How to Develop Your Team. Conference. Women in Cancer Immunotherapy Network (WIN) Leadership Institute. Seattle, WA, US.
- 2022. Pathway to Becoming a Physician Scientist. Conference. Summer Experience – Career Conversations. Houston, TX, US.
- 2022. Informative Clinical Trial Platform of Longitudinal Sampling to Accelerate Development of Therapeutics for Glioblastoma. Conference. BreakThrough Cancer Summit. Kiawah, SC, US.
- 2022. Breakout Discussion, "Not Your Usual Checkpoints". Conference. Parker Institute of Cancer Immunotherapy (PICI). Montage Healdsburg, CA, US.
- 2022. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. Panel Discussion on the Division of Cancer Medicine Hematology/Oncology Fellows Research Curriculum Series. Virtual Meeting, TX, US.
- 2022. Immunotherapy. Conference. U54 Online Personalized Cancer Medicine Intensive Course. Virtual Meeting, TX, US.
- 2021. Brainstorming Retreat. Conference. CCSG Development Therapeutics Program – DT Program Retreat. Houston, TX, US.
- 2021. Pathway of Response and Resistance to Immune Checkpoint Therapy. Conference. General Internal Medicine Group at their Clinical and Research Conference. Houston, TX, US.
- 2021. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. Enjoy Science Webinar Series. Houston, TX, US.
- 2021. Bladder Cancer Updates and Management. Conference. IHA Hematology Oncology at St. Joe's Brighton (formerly IHA Hematology Oncology Consultants - Brighton). Houston, TX, US.
- 2021. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. Conference. K12 Symposium, US.
- 2020. Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies Through Reverse Translational Studies. Conference, US.
- 2020. Tumor Specific Combination Strategy for Immune Checkpoint Therapy. Conference. The Parker Institute of Cancer Immunotherapy, Fall Retreat, TN, US.
- 2020. A Pilot Study Evaluating the Clinical, Immunological, and Epigenetic Impact of EZH1/2 Inhibition in Overcoming Resistance to Immune Checkpoint Therapy (ICT) in Genitourinary Malignancies. Conference. K-12 Symposium, US.
- 2020. Differential Epigenetic Regulation of Immune Microenvironment in Lymphoid versus Myeloid Rich Tumors. Conference. Frontiers in Cancer Immunotherapy. New York, NY, US.
- 2020. Epigenetic Regulation of Immune Microenvironment. Conference. Cancer Center Support Grant (CCSG) Immunology and Cancer Genetics & Epigenetics Retreat. Houston, TX, US.
- 2019. Arid1a Mutation Plus Cxcl13 Expression Act as Combinatorial Biomarkers to Predict Responses to Immune Checkpoint Therapy in Urothelial Carcinoma, Leading Edge in Cancer Research, Symposia on Cancer Research. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Update on Bladder Cancer Treatment & Management. Conference. Doctor's Hospital of Edinburg, TX. Edinburg, TX, US.
- 2018. Immunotherapy for Bladder Cancer. Conference. MD Anderson and OncInfo Roche Preceptorship Conference. Houston, TX, US.
- 2018. Modulation of EZH2 Expression in T Cells Improves Efficacy of Anti-CTLA-4 Therapy. Conference. Melvin Samuels Lectureship. Houston, TX, US.
- 2016. Epigenetic Changes in T Cells in Response to Immune Checkpoint Blockade Therapy. Conference. The Coffey - Holden Prostate Cancer Academy (CHPCA) Meeting. Coronado, CA, US.
- 2015. Ezh2 Inhibition Affects T Cell Differentiation. Conference. First Annual Immuno-Oncology Young Investigators' Forum. Chicago, IL, US.
- 2010. Role of Inflammation in Oncogenesis. Conference. Role of Inflammation in Oncogenesis: Role of inflammatory cells in NSCLC metastasis. Keystone, CO, US.
- 2009. Divergent Roles of Airway Epithelial MMP7 ad ATRA in Experimental Asthma. Conference. AAI 96th Annual Meeting. Seattle, WA, US.
- 2008. Role of MMP7 in Asthma Pathogenesis. Conference. AAI Experimental Biology 2008 Annual Conference. San Diego, CA, US.
International Presentations
- 2026. Cancer Awareness for Young Minds - Knowledge, prevention, and the power to protect yourself. Invited. Visakhapatnam, IN.
- 2026. Clinically Actionable Biomarkers for Precision Therapy in Bladder Cancer. Invited. Illuminate Oncology Town Hall 3.0. Mumbai, IN.
- 2026. Unlocking the Power of Immunotherapy: Science and Strategies for Rational Combinations. Invited. Illuminate Oncology Town Hall 3.0. Mumbai, IN.
- 2025. DS3201 With Ipilimumab In Patients With Refractory Genitourinary Tumors. Poster. ESMO Congress 2025. Berlin, DE.
- 2025. Epigenetic pathways regulating responses and resistance to immune-based therapies. Invited. 19th International Congress of Immunology. Vienna, AT.
- 2025. Harnessing Reverse Translational Strategies to Drive Precision Immunotherapy. Invited. Illuminate Oncology Townhall. Mumbia, IN.
- 2025. 6th Annual Congress of I-OSICON 2025, Bhubaneswar. Invited. 6th Annual Conference of Immuno-Oncology Society of India (I-OSI). Mumbai, IN.
- 2025. Reverse Translational Strategies to Improve Patient-Specific Response to Immune Checkpoint Therapy. Immuno-Oncology-Choosing Wisely and Precisely. Bhubaneswar, IN.
- 2024. Inagural United States-India Cancer Dialogue. Invited. Inagural United States-India Cancer Dialogue. New Delhi, IN.
- 2024. Targeting the Epigenetic Machinery to Modulate Anti-tumor Immunity. Invited. Oxford Centre for Immuno-Oncology seminar series. Oxford, GB.
- 2024. Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T cell Function. Co-Chair, Lessons Learned from Failed Clinical Trials. Whistler, CA.
- 2024. Targeting the Epigenetic Machinery to Improve Responses to Immune Checkpoint Therapy. Invited. Department of Biological Science Lecture Series. Kolkata, IN.
- 2024. Mechanisms of resistance to immunotherapy. Invited. Cancer Immunotherapy and Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies. Kochi, IN.
- 2024. Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance. Invited. Whistler, CA.
- 2023. Immune Checkpoint Therapy in Cancer. 2nd International Conference on Health & Allied Sciences. Lusaka, ZM.
- 2022. Renal Cell Carcinoma: Current Treatment Strategies and The Role of Immune Checkpoint therapy. Guwahati, IN.
- 2021. Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies. Invited. Haryana, IN.
- 2021. Targeting Epigenetic Machinery to Overcome Resistance to Immune Checkpoint Therapy. 2021 Beijing Cancer Immunotherapy Workshop. Beijing, CN.
- 2021. Metastatic RCC: Second Line and Beyond. Bangalore, IN.
- 2021. Role of Immune Checkpoint Therapy in Cancer Treatment. Jorhat, IN.
- 2019. Modulation of Immune Checkpoint Therapy Responses by Immune Cell Inherent Epigenetic Machinery. Keystone Symposia Conference on Cancer Immunotherapy. British Columbia, CA.
- 2019. Keystone Symposia on Molecular and Cellular Biology, Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2). Whistler, CA.
Grant & Contract Support
| Date: | 2027 - 2032 |
| Title: | Biological Aging as a Determinant of Hepatic Nanoparticle Clearance and Tumor Delivery |
| Funding Source: | National Cancer Institute |
| Role: | Co-I |
| ID: | FP00030212 |
| Date: | 2027 - 2027 |
| Title: | A New Precision Approach to Bladder Cancer: Biomarkers, Vaccines, and Immune Checkpoint Therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | FP00029913 |
| Date: | 2026 - 2029 |
| Title: | Reprogramming Tumor Proteostasis Through the SIK2/3-VCP Axis to Enhance immunotherapy Response in Ovarian Cancer |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | RP270186 |
| Date: | 2026 - 2029 |
| Title: | Targeting CAMKK2 for the Treatment of Advanced Prostate Cancer |
| Funding Source: | NIH |
| Role: | Collaborator |
| ID: | FP00025990_Res1 |
| Date: | 2026 - 2028 |
| Title: | A Spatial Transcriptomic Framework for Predicting Adjuvant Pembrolizumab Benefit in Aggressive Variants of Localized Renal Cell Carcinoma |
| Funding Source: | Urology Care Foundation |
| Role: | Mentor |
| ID: | FP00029242 |
| Date: | 2026 - 2029 |
| Title: | Advancing Cancer Careers through Education, Learning, Exploration, Research, and Training Excellence (ACCELERATE) Post-Baccalaureate Fellowship |
| Funding Source: | American Cancer Society, National (ACS) |
| Role: | Mentor |
| ID: | FP00025930 |
| Date: | 2023 - 2028 |
| Title: | Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) Program |
| Funding Source: | NIH/NCI |
| Role: | Preceptor |
| ID: | 5 R25 CA 265800 - 03; Project: 00015483 |
| Date: | 2023 - 2028 |
| Title: | Targeting Epigenetic Machinery to Overcome Myeloid Cell-Mediated Resistance to Anti-PD-1 Therapy in GBM |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 R37 CA 279192 - 03; Project: 00014792 |
| Date: | 2023 - 2030 |
| Title: | James P. Allison Institute Assistant Member Research Support Package |
| Funding Source: | James P. Allison Institute |
| Role: | PI |
| ID: | Fund: 128234 |
| Date: | 2023 - 2025 |
| Title: | Targeting B7-H3 in Aggressive Variant Prostate Cancer |
| Funding Source: | Prostate Cancer Foundation |
| Role: | Multiple Principal Investigator |
| ID: | 22CHAL09; Project: 00014958 |
| Date: | 2022 - 2025 |
| Title: | PC210079: An Integrated Genomic Definition and Therapeutic Strategy for Androgen Indifferent Prostate Cancers |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-22-1-0259; FP00014475; Project: 00014616 |
| Date: | 2022 - 2025 |
| Title: | Development of Tertiary Lymphoid Structures (TLS) as a Biomarker to Select Patients with Bladder Cancer for Treatment with Immune Checkpoint Therapy |
| Funding Source: | The University of Texas Foundation |
| Role: | PI |
| ID: | FP00017501 Baker Hughes Foundation; Project: 00014593 |
| Date: | 2022 - 2025 |
| Title: | Informative Clinical Trial Platform of Longitudinal Sampling to Accelerate Development of Therapeutics for Glioblastoma |
| Funding Source: | BreakThrough Cancer |
| Role: | Group Leader |
| ID: | FP00015175; Project: 00014357 |
| Date: | 2021 - 2026 |
| Title: | Improving Anti-Tumor Responses to Immunotherapy Using the Combination Biomarker ARID1A and CXCL13 |
| Funding Source: | Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation |
| Role: | Multiple Principal Investigator |
| ID: | FP00012831; Project: 00013139 |
| Date: | 2021 - 2023 |
| Title: | A Study to Investigate the Role of Epigenetic Reprogramming in Improving Responses to Immune Checkpoint Therapy in Metastatic Renal Cell Carcinoma |
| Funding Source: | Cancer Research Institute |
| Role: | PI |
| ID: | CRI3767; Project: 00013067 |
| Date: | 2021 - 2023 |
| Title: | A Study to Investigate the Role of Epigenetic Reprogramming in Improving Responses to Immune Checkpoint Therapy in Metastatic Bladder Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | RCTS 00060089; Fund: 123930 |
| Date: | 2021 - 2026 |
| Title: | Start-Up Funds |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | Fund: 123536 |
| Date: | 2021 - 2026 |
| Title: | Physician Scientist Award |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | Fund: 123569 |
| Date: | 2020 - 2021 |
| Title: | A Pilot Study Evaluating the Clinical, Immunological, and Epigenetic Impact of EZH2 Inhibition in Overcoming Resistance to Immune Checkpoint Therapy in Genitourinary Malignancies |
| Funding Source: | Paul Calabresi Clinical Oncology Research Career Development Award |
| Role: | Recipient |
| ID: | Project: 00011493 |
| Date: | 2018 - 2021 |
| Title: | Epigenetic Modulation with EZH2 Inhibition Can Overcome Resistance to Immune Checkpoint Therapy |
| Funding Source: | Emerson Collective Research Foundation |
| Role: | PI |
| ID: | RCTS: 00056312; Fund: 60065-80-121454-19 |
| Date: | 2018 - 2022 |
| Title: | Epigenetic Immunomodulation in Immunocheckpoint Therapy Responses |
| Funding Source: | Khalifa Physician Scientist Award |
| Role: | PI |
| ID: | Fund: 121373 |
Selected Publications
Peer-Reviewed Articles
- Ha J, Wang Y, Ma Y, Wu A, Dong S, Jeong SD, Edwards JL, Chang M, Chang YT, Wang X, Dufilho M, Najarro Torres M, McCabe S, Deng W, Grippin AJ, Weinberg JS, Raza SM, DeMonte F, McCutcheon IE, Prabhu S, Ferguson SD, Ene CI, Akdemir K, Basu S, Jindal S, Schrank BR, Hu J, Goswami S, Puduvalli VK, Lang FF, Huntoon K, Sharma P, Kim BYS, Jiang W. Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. Nat Commun 17(1), 2026. e-Pub 2026. PMID: 41803138.
- Grewal K, Moura Nascimento Santos MJ, Chauhan PK, Yu K, Tannir NM, Mukhida SS, Venkatesh N, Shah AY, Zurita AJ, Johns AC, Campbell MT, Goswami S, Gao J, Jonasch E, McQuade JL, Alhalabi O, Msaouel P, Hahn AW. Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. J Immunother Cancer 14(3), 2026. e-Pub 2026. PMID: 41775432.
- Wang, J, Johns, AC, Alhalabi, O, Gao, J, Goswami, S, Hahn, AW, Jonasch, E, Campbell, M, Desai, M, Lin, JK, Msaouel, P, Shah, AY, Zurita-Saavedra, A, Tannir, NM. A phase II trial of nivolumab, ipilimumab and cabozantinib in patients with brain metastases from renal cell carcinoma. Journal of Clinical Oncology 44:492, 2026. e-Pub 2026.
- Jonasch, E, Tannir, NM, Hahn, AW, Goswami, S, Msaouel, P, Shah, AY, Tidwell, R, Hwang, H, Wood, LM, Syed, M, Solley, T, Fares, S, Lewis, LS, Brooks, E, Bartell, H, George, DJ, Haas, NB, Harrison, M, Hammers, HJ, Rini, BI. A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma. Journal of Clinical Oncology 44:TPS580-TPS580, 2026. e-Pub 2026.
- Dizman, N, Tidwell, R, Sheth, RA, Alhalabi, O, Corn, P, Campbell, M, Goswami, S, Johns, AC, Jonasch, E, Lin, JK, Shah, AY, Wang, J, Zurita-Saavedra, A, Gao, J, Tannir, NM, Hahn, AW, Msaouel, P. Ivonescimab in metastatic clear cell renal cell carcinoma (mccRCC) after immune checkpoint inhibitor therapy. Journal of Clinical Oncology 44:TPS573-TPS573, 2026. e-Pub 2026.
- Moussa MJ, Andreev-Drakhlin AY, Venkatesan AM, Matin SF, Xiao L, Tidwell RSS, Shah AY, Adriazola AC, Shaw L, Gao J, Lin JK, Goswami S, Msaouel P, Guo CC, Tannir NM, Siefker-Radtke AO, Alhalabi O, Campbell MT. Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability. JCO Precis Oncol 10(3):e2500772, 2026. e-Pub 2026. PMID: 41911516.
- Singh P, D'Rozario R, Chakraborty B, Meher S, Raychaudhuri D, Tannir AJ, Li Y, Majumdar A, Hawkins J, Xiong Y, Lorenzi P, Sharma P, Akdemir K, Pilie P, Jain AK, Lee BHL, Goswami S. Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer. Nat Commun 17(1):1382, 2026. e-Pub 2026. PMID: 41501085.
- Carriere P, Alhalabi O, Gao J, Shah A, Goswami S, Campbell M, Lin R, Mayo L, Mohamad O, Hoffman K, Mok H, Lozano C, Kamat A, Navai N, Bree K, Lee B, Guo C, Rooney M, Tang C, Choi S, Hassanzadeh C. Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract. Bladder Cancer 12(1):23523735251414249, 2026. e-Pub 2026. PMID: 41550986.
- Yu, K, Basu, S, Baquer, G, Ahn, R, Gantchev, J, Jindal, S, Regan, MS, Abou-Mrad, Z, Prabhu, MC, Williams, MJ, D’Souza, AD, Malinowski, S, Hopland, K, Elhanati, Y, Stopka, SA, Stortchevoi, A, Couturier, C, He, Z, Sun, JJ, Chen, Y, Espejo, A, Chow, KH, Yerrum, S, Kao, PL, Kerrigan, BP, Norberg, L, Nielsen, D, Douville, C, Sharma, P, Giantini-Larsen, AM, Hu, J, Ayoub, G, Elharouni, D, Polk, MJ, Landivar, AM, Masud, N, Ling, AL, Triggs, D, Piranlioglu, R, Ball, A, Soni, H, Solomon, IH, Vasquez, KL, Vogelzang, J, Puduvalli, VK, Huse, J, Kim, YB, Goswami, S, Lang Jr, FF, Sharma, P. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40295505.
- Ling, AL, Gantchev, J, Prabhu, MC, Basu, S, Ahn, R, Holdhoff, M, Masud, N, Ball, A, Nikas, O, Villa, GR, Regan, MS, Baquer, G, Ayoub, G, Whittaker, CA, Abou-Mrad, Z, Santos, A, Couturier, C, Elharouni, D, Vogelzang, J, Yu, K, Chen, H, He, Z, Jiang, W, Lucas, CG, Sax, HE, Lang Jr, FF, Puduvalli, VK, Tabar, V, Brennan, CW, Boire, A, Holdhoff, M, Bettegowda, C, Cima, M, Solomon, IH, Yuan, Y, Tak, PP, Sharma, P, White, F, Ligon, KL, Agar, NY, Espejo, A, Sun, JJ, Chen, Y, Jindal, S, Huse, J, Goswami, S, Akdemir, KC, Hu, J, Sharma, P, Buchold, G. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Science translational medicine 17(819), 2025. e-Pub 2025. PMID: 41061048.
- Liu J, Herbrich S, Basu S, Chen Y, Nagarajan A, Anandhan S, Goswami S, Xiong L, Guan B, Sharma P. Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy. Sci Adv 11(37), 2025. e-Pub 2025. PMID: 40929270.
- Tang C, Sherry AD, Seo A, Hara K, Choi H, Liu S, Sun X, Montoya A, Ludmir EB, Shah AY, Jonasch E, Zurita AJ, Kovitz C, Alhalabi O, Goswami S, Hahn AW, Campbell MT, Hernandez A, Nead KT, Loo PV, Su S, Battey CJ, LaBella ML, Ratzel S, Acevedo A, Genovese G, Sircar K, Karam JA, Tannir NM, Msaouel P. Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. Lancet Oncol 26(10):1289-1299, 2025. e-Pub 2025. PMID: 40915303.
- Poon, C, Herbrich, SM, Chen, Y, Hossain, A, Fuller, GN, Jindal, S, Basu, S, Ledbetter, D, Macaluso, M, Phillips, LM, Gumin, J, He, Z, Parker Kerrigan, BC, Singh, S, Singh, P, Zaman, MF, Ng Tang, D, Goswami, S, Lang Jr, FF, Sharma, P. Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome. Cancer Immunology Research 13(6):804-820, 2025. e-Pub 2025. PMID: 40131028.
- Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun 16(1):1846, 2025. e-Pub 2025. PMID: 39984485.
- Moussa MJ, Khandelwal J, Wilson NR, Malikayil KL, Surasi DS, Bathala TK, Lin Y, Rao P, Tamboli P, Sircar K, Ajufo H, Elsayes KM, Shah A, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. J Immunother Cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
- Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Futreal A, Wang L, Tannir NM, Sharma P. Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma. Res Sq, 2024. e-Pub 2024. PMID: 39606482.
- Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo A, Im JS, Goswami S. Histone lactylation drives CD8(+) T cell metabolism and function. Nat Immunol 25(11):2140-2151, 2024. e-Pub 2024. PMID: 39375549.
- Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49:100866, 2024. e-Pub 2024. PMID: 39403573.
- Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus 11(1):150-158, 2024. e-Pub 2024. PMID: 39307587.
- Anandhan S, Herbrich SM, Goswami S, Guan B, Chen Y, Macaluso M, Jindal S, Natarajan SM, Andrewes S, Xiong L, Nagarajan A, Basu S, Tang DN, Liu J, Min J, Maitra A, Sharma P. TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun 15(1):5291, 2024. e-Pub 2024. PMID: 38987547.
- Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell M, Zurita-Saavedra A, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid and/or Rhabdoid Dedifferentiation after Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2024. PMID: 38035767.
- Hanif IH, Abdelrahim S, Al Shaarani M, Lu H, Ahmad R, Goswami S, Abudayyeh A. Immune Checkpoint Therapy–Induced Lupus Nephritis. Kidney Int Rep 9(5):1534-1537, 2024. e-Pub 2024. PMID: 38707799.
- Moussa, MJ, Chen, AH, Grana, AK, Gao, J, Shah, AY, Corn, P, Tannir, NM, Goswami, S, Wang, J, Araujo, JC, Kamat, A, Navai, N, Pettaway, CA, Adibi, M, Czerniak, BA, Guo, CC, Siefker-Radtke, AO, Campbell, M, Alhalabi, O. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
- Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
- Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso M, He Z, Jindal S, Lang FF Jr, Basu S, Sharma P. Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nature Cancer 4(10):1455-1473, 2023. e-Pub 2023. PMID: 37653141.
- Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell M, Shah AY, Corn P, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641), 2022. e-Pub 2022. PMID: 35442707.
- Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
- Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7):e002850, 2021. e-Pub 2021. PMID: 34326169.
- Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 1489(1):30-47, 2021. e-Pub 2021. PMID: 33184911.
- Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol 11:621591, 2021. e-Pub 2021. PMID: 33747934.
- Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 2020. e-Pub 2020. PMID: 32554706.
- Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
- Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res 7(11):1803-1812, 2019. e-Pub 2019. PMID: 31466995.
- Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
- Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 5(11):e1234570, 2016. e-Pub 2016. PMID: 27999749.
- Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2013. PMID: 23204236.
- Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Song LZ, Redding D, Singh B, Sur S, Woodruff P, Dong C, Corry DB, Kheradmand F. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol 10(5):496-503, 2009. e-Pub 2009. PMID: 19329997.
- Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13(5):567-9, 2007. e-Pub 2007. PMID: 17450149.
- Zhao L, Leung JK, Yamamoto H, Goswami S, Kheradmand F, Vu TH. Identification of P311 as a potential gene regulating alveolar generation. Am J Respir Cell Mol Biol 35(1):48-54, 2006. e-Pub 2006. PMID: 16484684.
- Sharma M, Batra J, Mabalirajan U, Goswami S, Ganguly D, Lahkar B, Bhatia NK, Kumar A, Ghosh B. Suggestive evidence of association of C-159T functional polymorphism of the CD14 gene with atopic asthma in northern and northwestern Indian populations. Immunogenetics 56(7):544-7, 2004. e-Pub 2004. PMID: 15378299.
Review Articles
- Pauken, KE, Alhalabi, O, Goswami, S, Sharma, P. Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit. Cancer cell 43(4):623-640, 2025. e-Pub 2025. PMID: 40118048.
- Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol 25(12):2186-2199, 2024. e-Pub 2024. PMID: 39587347.
- Goswami S, Sharma P. Loss of ARID1A 'loops' in STING. Trends Immunol 45(8):568-570, 2024. e-Pub 2024. PMID: 39060141.
- Goswami S. KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy. Nat Cancer 4(10):1408-1409, 2023. e-Pub 2023. PMID: 37700093.
- Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy—current perspectives and future directions. Cell 186(8):1652-1669, 2023. e-Pub 2023. PMID: 37059068.
- Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol 23(2):106-120, 2023. e-Pub 2023. PMID: 35697799.
- Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. e-Pub 2022. PMID: 35290784.
- Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. e-Pub 2021. PMID: 33811120.
- Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24(2):123-124, 2018. e-Pub 2018. PMID: 29414936.
- Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science 357(6349), 2017. e-Pub 2017. PMID: 28751597.
- Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Prostate 77(2):123-144, 2017. e-Pub 2017. PMID: 27679977.
- Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 22(2):117-20, 2016. e-Pub 2016. PMID: 27111907.
Abstracts
- Goswami S, Saj F, Kimana Q, Kong E, Xiao L, Shah NM, Lee SS, Hu ZI, Duda GD, Kwong L, Korkut A, Javle MM. Association between obesity, molecular subtype, and immunotherapy outcomes in intrahepatic cholangiocarcinoma: The obesity paradox, 2026. e-Pub 2026.
- Singh P, D’Rozario R, Chakraborty B, Meher S, Raychaudhuri D, Tannir AJ, Li Y, Majumdar A, Hawkins J, Xiong Y, Lorenzi P, Sharma P, Akdemir K, Pilie P, Jain AK, Lung Lee BH, Goswami S. Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer?, 2026. e-Pub 2026.
- Moussa MJ, Diab MS, Mostafa AG, Chen AH, Grana AK, Msaouel P, Shah AY, Gao J, Meric-Bernstam F, Goswami S, Desai MD, Kamat AM, Pettaway CA, Guo CC, Tannir NM, Elsayes KM, Siefker-Radtke AO, Campbell MT, Alhalabi O. Comprehensive clinical and genomic characterization of advanced urachal and non-urachal adenocarcinomas of the urinary tract, 2025. e-Pub 2025.
- Jiang CY, Zhang Y, Yu K, Mei Y, Qiao W, Moussa MJ, Chen J, Wang R, Zhao J, Shah AY, Goswami S, Guo CC, Siefker-Radtke AO, Campbell MT, Wang L, Alhalabi O, Gao J. Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer, 2025. e-Pub 2025.
- Goswami S, Raychaudhuri D, Singh P, Tannir AJ, Meher S. Differential roles of histone lactylation in regulating CD8 T cell effector functions and exhaustion, 2025. e-Pub 2025.
- Goswami S, Singh P, Raychaudhuri D, Chakraborty B, Tannir AJ, Meher S, Majumdar A, Hwakins J, Xiong Y, Lorenzi PL, Sharma P, Pilié PG. Genomic and metabolic effects of KDM6A loss regulates differential responses to immune checkpoint therapy and chemotherapy in bladder cancer, 2025. e-Pub 2025.
- Goswami S. The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi), 2025. e-Pub 2025.
- Goswami S, Moussa MJ, Andreev-Drakhlin A, Shah AY, Matin SF, Adriazola AC, Shaw L, Campbell ML, Msaouel P, Corn PG, Lin JK, Gao J, Guo CC, Tannir NM, Siefker-Radtke AO, Alhalabi O, Campbell MT. Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI), 2025. e-Pub 2025.
- Moussa MJ, Khandelwal J, Wilson N, Malikayil KL, Surasi DS, Bathala TK, Lin Y, Ajufo H, Elsayes KM, Shah AY, Johns A, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma, 2025. e-Pub 2025.
- Grewal K, Chauhan PK, Mukhida SS, Tannir NM, Venkatesh N, Shah AY, Zurita AJ, Johns A, Campbell MT, Goswami S, Gao J, Jonasch E, McQuade JL, Alhalabi O, Msaouel P, Hahn AW. The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi, 2025. e-Pub 2025.
- Moussa MJ, Subramanian NG, Haro-Silerio J, Chen L, Shah AY, Gao J, Corn PG, Goswami S, Msaouel P, Wang J, Kamat AM, Guo CC, Tannir NM, Siefker-Radtke AO, Alhalabi O, Campbell MT. Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience, 2024. e-Pub 2024.
- Moussa MJ, Wilson NR, Xiao L, Tabet GC, Gao J, Shah AY, Corn PG, Goswami S, Msaouel P, Tannir NM, Lee BH, Kamat AM, Adibi M, Dinney CP, Hansel DE, Guo CC, Siefker-Radtke AO, Campbell MT, Alhalabi O. Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO), 2024. e-Pub 2024.
- Moussa MJ, Chen AH, Grana AK, Gao J, Shah AY, Corn PG, Tannir NM, Goswami S, Wang J, Araujo JC, Kamat AM, Navai N, Pettaway CA, Adibi M, Czerniak B, Guo CC, Siefker-Radtke AO, Campbell MT, Alhalabi O. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience, 2024. e-Pub 2024.
- Goswami S. KDM6B Mediated Epigenetic Reprogramming of Intratumoral Myeloid Cells Improves Response to Immune Checkpoint Therapy in Glioblastoma, 2023. e-Pub 2023.
- Johns A, Campbell MT, Msaouel P, Jonasch E, Hahn AW, Gao J, Shah AY, Goswami S, Zurita AJ, Pagliaro LC, Bilen MA, Venkatesan AM, Rao P, Tamboli P, Sircar K, Tidwell RS, Tannir NM. CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC) 41(16), 2023. e-Pub 2023.
- Jiang C, Alhalabi O, Haro-Silerio J, Qiao W, Shah AY, Siefker-Radtke AO, Gao J, Goswami S, Alva AS, Koshkin VS, Guo C, Campbell MT. Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV) 41(16_Suppelment), 2023. e-Pub 2023.
- Wilson NR, Khandelwal J, Xiao L, Shah AY, Gao J, Goswami S, Kovitz CA, Guo C, Czerniak B, Logothetis C, Corn PG, Tannir NM, Siefker-Radtke AO, Alhalabi O. Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC), 2023. e-Pub 2023.
- Wang J, Campbell MT, Shah AY, Goswami S, Msaouel P, Alhalabi O, Hahn AW, Kovitz CA, Jana BRP, Arajo JC, Gao J, Zurita AJ, Jonasch E, Corn PG, Tannir NM. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases 41(6), 2023. e-Pub 2023.
- Shah AY, Campbell MT, Tidwell R, Siefker-Radtke AO, Goswami S, Alhalabi O, Adriazola AC, Shaw L, Ye Y, Chen J, Yan X, Wang L, Gao J. A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer 40(16), 2022. e-Pub 2022.
- Alhalabi O, Wilson N, Xiao L, Navai N, Kamat AM, Shah AY, Araujo JC, Wang J, Goswami S, Gao J, Wang J, Guo C, Czerniak B, Corn PG, Logothetis C, Dinney CP, Campbell MT, Tannir NM, Siefker-Radtke AO. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC), 2022. e-Pub 2022.
- Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell MT, Shah AY, Wang J, Jonasch E, Arajo JC, Wang J, Gao J, Goswami S, Msaouel P, Tannir NM. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC) 40(6), 2022. e-Pub 2022.
- Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang Z, Natarajan S, Xiong L, Guan B, Singh S, Saci A, Allison JP, Galsky MD, Sharma P. Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer, 2021. e-Pub 2021.
- Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO, Goswami S, Xiao L, Venkatesan AM, Campbell MT. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI) 39(6), 2021. e-Pub 2021.
- Msaouel P, Gao J, Yuan Y, Siefker-Radtke AO, Jonasch E, Goswami S, Zurita AJ, Campbell MT, Shah AY, Corn PG, Ramos C, Yan X, Chin C, Der-Torossian H, Tannir NM. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies, 2021. e-Pub 2021.
- Goswami S. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine, 2020. e-Pub 2020.
- Siddiqui B, Gheeya JS, Goswamy R, Subudhi SK, Gao J, Shah AY, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Siefker-Radtke AO, Sharma P, Tannir N. Immune Checkpoint Therapy (ICT) re-Challenge after immune-related adverse events (irAEs) in genitourinary cancers: safety and efficacy, 2020. e-Pub 2020.
- Goswami S, Zhao H, Zhang X, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy, 2016. e-Pub 2016.
- Chen L, Goswami S, Yi X, Byers L, Diao L, Roybal J, Ungewiss C, Peng D, Wang J, Wistuba I, Chen L, Ullrich S, Heymach J, Kurie J, Win XF, Gibbons D. A big role in tumor immune microenvironment of a small non-coding RNA: microRNA-200. Cancer Immunol Res 3(10_Supplement), 2015. e-Pub 2015.
- Goswami S, Shi L, Sharma P. Ezh2 affects T cell differentiation, 2015. e-Pub 2015.
- Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Goswami S, Cortiz MA, Welsh J, Kurie JM, Heymach J, Wistuba II. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers, 2014. e-Pub 2014.
- Gibbons DL, Chen L, Goswami S, Ahn YH, Byers LA, Diao L, Wang J, Cortez A, Roybal J, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba I, Heymach JV, Kurie JM, Qin FXF. microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis. Clin Cancer Res 20(2_Supplement), 2014. e-Pub 2014.
- Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn YH, Byers LA, Win L, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, Chen L, Wistuba II, Heymach J, Kurie JM, Qin FXF. Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis, 2014. e-Pub 2014.
- Massarelli E, Erez B, Goswami S, Kurie JM. CXCR2 inhibition decreases invasion and metastasis of a KRAS/p53-mutant lung adenocarcinoma cell line in vitro and in vivo. Cancer Res 72(8_Supplement), 2012. e-Pub 2012.
- Goswami S, Ahn YH, Lin W, Mediavila-Varela M, Zhang X, Baruch E, Dwyer DW, Ungewiss C, Patel MP, Antonia S, Qin XF, Kurie JM. miR-200 suppression in tumor cells promotes metastasis by trigging intra-tumoral CD8+ T cell anergy, 2011. e-Pub 2011.
- Goswami S, Lin W, Dwyer D, Qin XF, Kurie JM. Role of Inflammatory Cells in Lung Cancer Metastasis, 2010. e-Pub 2010.
- Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Sur S, Woodruff C, Dong C, Corry DB, Kheradmand F. Divergent roles of airway epithelial MMP7 and retinoic acid in experimental asthma. J Immunol 182(1):Supplement, 2009. e-Pub 2009.
- Goswami S, Barranco W, Greenlee KJ, Seryshev AB, Corry DB, Kheradmand F. Role of matrix-metalloprotease-7 in a model of experimental asthma, 2008. e-Pub 2008.
- Goswami S, Barranco W, Lee SL, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema, 2007. e-Pub 2007.
- Goswami S, Barranco W, Lee SL, Grudo A, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema, 2007. e-Pub 2007.
- Lee SL, Goswami S, Grumelli S, Corry DB, Kheradmand F. Elastin derived peptide mediate autoimmune basis for smoking-induced emphysema in human, 2006. e-Pub 2006.
- Singh P, Rozario RD, Chakraborty B, Meher S, Raychaudhuri D, Tannir AJ, Majumdar A, Hawkins J, Xiong Y, Lorenzi P, Sharma P, Pilie P, Lee B, Goswami S. Loss of KDM6A alter genomic and metabolic landscapes to regulate response to therapeutic peturbations in bladder cancer. James P. Allison Institute Symposium.
Book Chapters
- Sharma A, Campbell M, Yee C, Goswami S, Sharma P. Immunotherapy of Cancer. In: Clinical Immunology: Principles and Practice. 5th Edition, 1033-1048.e1, 2019.
- Goswami S, Allison JP, Sharma P. Novel and Other Cancer Topics of Interest: Immuno-Oncology. In: The MD Anderson Manual of Medical Oncology: Third Edition. Third Edition. The McGraw-Hill Companies, Inc, 995-1002, 2016.
- Sharma P, Subudhi SK, Peggs K, Goswami S, Gao JJ, Quezada S, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition. 9th Edition. Hong WK, Bast R, Hait WN Wiley, 2015.
- Massarelli E, Goswami S, Piha-Paul S. Section 1: Targets by Organ Site: Head and Neck Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.
Patient Reviews
CV information above last modified August 27, 2026